Aiming radiation precisely may buy time for men whose prostate cancer returns in a few spots

When prostate cancer comes back in only a few places, a targeted radioactive drug combined with precision radiotherapy delayed the cancer's spread in a randomised Phase 2 trial led by UCLA's Amar Kishan, published in European Urology — with no new safety concerns on longer follow-up. The idea is to treat both the tumours doctors can see and the microscopic ones they cannot, potentially postponing harsher therapy.